Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab
نویسندگان
چکیده
منابع مشابه
Eculizumab in atypical hemolytic-uremic syndrome.
n engl j med 369;14 nejm.org october 3, 2013 1377 [CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days. We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations. We agree with Jeong that there may be important differences according to the patients’ ...
متن کاملEculizumab for atypical hemolytic-uremic syndrome.
n engl j med 360;5 nejm.org january 29, 2009 542 myocardial infarction or coronary death, a 24% decrease in the need for coronary bypass surgery, and a 17% decrease in the rate of fatal or nonfatal stroke.2 The recently reported results of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin (20 mg per day) show th...
متن کاملCase report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by chronic, uncontrolled activation of the alternative complement pathway, leading to thrombotic microangiopathy. Renal impairment and progression to end-stage renal disease are common in untreated patients with aHUS, and extrarenal manifestations are being increasingly characterized in the literature. Ocular involvement remains...
متن کاملCritical appraisal of eculizumab for atypical hemolytic uremic syndrome.
The biology of atypical hemolytic uremic syndrome has been shown to involve inability to limit activation of the alternative complement pathway, with subsequent damage to systemic endothelial beds and the vasculature, resulting in the prototypic findings of a thrombotic microangiopathy. Central to this process is the formation of the terminal membrane attack complex C5b-9. Recently, application...
متن کاملAtypical hemolytic uremic syndrome and eculizumab therapy in children
Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury. Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical HUS (aHUS) caused by genetic complement dysregulation has been studied recently. aHUS is a rare, chronic, and devastating disorder that progressively damages systemic organs, resulting in stroke, end-stage renal disease...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Case Reports
سال: 2021
ISSN: 1941-5923
DOI: 10.12659/ajcr.929616